Abstract:Importance: The degree to which health and economic outcomes of musculoskeletal disorders are attributable to high body mass index (BMI) has not been quantified on a global scale. Objective: To estimate global health and economic outcomes associated with musculoskeletal disorders-low back pain (LBP), gout, and osteoarthritis attributable to high BMI in 2019. Design, setting, and participants: This cross-sectional study used data of 192 countries and territories from the Global Burden of Diseases, Injuries, and Risk Factors Study, World Health Organization Global Health Expenditure, World Bank, and International Labour Organization databases. Data analyses were conducted from February 24 to June 16, 2022. Main outcomes and measures: Prevalence, years lived with disability (YLDs), health care costs, and productivity losses due to morbidity from LBP, gout, and osteoarthritis attributable to high BMI by region and country. Prevalence and YLDs were calculated with the population attributable fraction approach. The economic burden, including health care costs and productivity losses due to morbidity, was also quantified. Health care costs borne by the public, private, and out-of-pocket sectors were estimated based on their corresponding payment shares. Productivity losses were estimated based on the output per worker. A sensitivity analysis was conducted to arrive at the base, minimum, and maximum estimates (ie, uncertainty interval [UI]) by using the mean, lower, and upper bounds of all input variables. Results: High BMI was estimated to be responsible for 36.3 million (UI, 18.4-61.0 million), 16.9 million (UI, 7.5-32.5 million), and 73.0 million (UI, 32.4-131.1 million) prevalent cases of LBP, gout, and osteoarthritis, respectively, which accounted for 7.3 million (UI, 3.0-15.0 million) YLDs across 192 countries and territories in 2019. Globally, the YLDs of musculoskeletal disorders attributable to high BMI accounted for 1.0% of all-cause YLDs in the working-age population aged 15 to 84 years. The global total costs of musculoskeletal disorders attributable to high BMI reached $180.7 billion (UI, $83.8-$333.1 billion), including $60.5 billion (UI, $30.7-$100.5 billion) in health care costs and $120.2 billion (UI, $53.1-$232.7 billion) in productivity losses. In terms of the global health care costs, 58.9% ($35.6 billion; UI, $17.8-$59.6 billion) was borne by the public sector, 24.0% ($14.5 billion; UI, $7.8-$23.2 billion) by the private sector, and 17.1% ($10.3 billion; UI, $5.1-$17.6 billion) by the out-of-pocket sector. On average, the total costs accounted for 0.2% of global gross domestic product. Great inequalities in the disease and economic burden existed across regions and countries. Nearly 80% of global health care (82.4%) and morbidity-related costs (82.9%) were paid by high-income countries, whereas more than 60% (61.4%) of global YLDs occurred in middle-income countries. Conclusions and relevance: In this cross-sectional study of 192 countries and territories, a substantial amount of the health and economic impact of musculoskeletal disorders was attributable to high BMI. Developing effective policies and active participation from health professionals to prevent excessive weight gain are needed. More available estimates are also needed to facilitate a global analysis.

Global burden of early-onset osteoarthritis, 1990-2019: results from the Global Burden of Disease Study 2019

Global burden of osteoarthritis from 1990 to 2019 attributable to high body mass index

Epidemiological trends of osteoarthritis at the global, regional, and national levels from 1990 to 2021, with a projection from 2021 to 2050

Disease burden of osteoarthritis of the knee and hip due to a high body mass index in China and the USA: 1990–2019 findings from the global burden of disease study 2019

Trends and cross-country inequalities in the global burden of osteoarthritis, 1990-2019: A population-based study

A comparison of the burden of knee osteoarthritis attributable to high body mass index in China and globally from 1990 to 2019

Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017

Burden of knee osteoarthritis in 204 countries and territories, 1990–2019: Results from the Global Burden of Disease Study 2019

Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of gout and its risk factor, 1990 to 2050

The Burden, Trends, and Risk Factors for Osteoarthritis in China from 1990 to 2019 and Its Predictions until 2035

Health and Economic Outcomes Associated With Musculoskeletal Disorders Attributable to High Body Mass Index in 192 Countries and Territories in 2019

Evaluation of osteoarthritis disease burden in China during 1990‐2019 and forecasting its trend over the future 25 years

Global Burden of Disease Study 2019: An opportunity to understand the growing prevalence and impact of hip, knee, hand and other osteoarthritis in Australia

Global Burden of osteoarthritis associated with high body mass index in 204 countries and territories, 1990–2019: findings from the Global Burden of Disease Study 2019

Global burden of osteoarthritis in adults aged 30 to 44 years, 1990 to 2019: results from the Global Burden of Disease Study 2019

Temporal trends in the disease burden of osteoarthritis from 1990 to 2019, and projections until 2030

Burden of osteoarthritis in China, 1990–2019: findings from the Global Burden of Disease Study 2019

Global burden of osteoarthritis: Prevalence and temporal trends from 1990 to 2019

The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study

Global, regional, and national burdens of hip osteoarthritis from 1990 to 2019: estimates from the 2019 Global Burden of Disease Study

Burden of Osteoarthritis in China, 1990–2017: Findings from the Global Burden of Disease Study 2017